Create Free Account

By creating account you will get access to hot stocks & personalised emails

Vita Life Sciences Ltd

Healthcare AU VLS

2.09AUD
0.04(1.95%)

Last update at 2024-05-13T00:11:00Z

Day Range

2.042.09
LowHigh

52 Week Range

1.362.50
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 10.74M 11.20M 8.16M 4.43M 4.33M
Minority interest -0.25700M 0.04M -0.27800M -0.06500M 0.03M
Net income 7.08M 8.29M 6.09M 3.14M 2.44M
Selling general administrative 16.69M 14.65M 14.01M 14.67M 13.47M
Selling and marketing expenses 10.42M 7.57M 6.16M 7.38M 6.74M
Gross profit 39.74M 34.81M 29.27M 27.90M 27.64M
Reconciled depreciation 0.60M 0.41M 0.55M 0.60M 0.40M
Ebit 10.77M 11.31M 8.32M 4.57M 4.46M
Ebitda 11.37M 11.71M 8.88M 5.18M 4.87M
Depreciation and amortization 0.60M 0.41M 0.55M 0.60M 0.40M
Non operating income net other - - - - -
Operating income 10.77M 11.31M 8.32M 4.57M 6.08M
Other operating expenses 56.17M 46.09M 38.94M 38.34M 35.08M
Interest expense 0.03M 0.10M 0.17M 0.15M 0.13M
Tax provision 3.40M 2.95M 2.30M 1.33M 1.90M
Interest income 0.13M 0.08M 0.19M 0.02M 0.02M
Net interest income 0.10M 0.04M 0.03M -0.01500M -0.02100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.40M 2.95M 2.30M 1.33M 1.90M
Total revenue 66.89M 57.10M 46.48M 42.45M 41.15M
Total operating expenses 29.02M 23.80M 21.73M 23.79M 21.57M
Cost of revenue 27.15M 22.29M 17.21M 14.55M 13.51M
Total other income expense net -0.03400M -0.10500M -0.16600M -0.14600M -1.74600M
Discontinued operations - - - - -
Net income from continuing ops 7.34M 8.25M 5.86M 3.09M 2.43M
Net income applicable to common shares 7.08M 8.29M 6.09M 3.14M 2.44M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 59.81M 51.80M 45.27M 39.10M 36.51M
Intangible assets - 0.01000M 0.00000M 0.01M 0.01M
Earning assets - - - - -
Other current assets 1.29M 0.47M 0.31M 0.25M 0.26M
Total liab 16.48M 15.30M 14.85M 14.66M 13.98M
Total stockholder equity 43.40M 36.57M 30.75M 24.72M 22.60M
Deferred long term liab - - - 0.01M 0.01M
Other current liab 6.33M 10.06M 3.52M 4.03M 4.58M
Common stock 42.57M 41.90M 41.63M 41.59M 42.25M
Capital stock - 41.90M 41.63M 41.59M 42.25M
Retained earnings -2.76900M -8.48200M -12.52800M -17.92500M -22.04600M
Other liab - 0.14M 0.20M 0.17M 0.16M
Good will - - - - -
Other assets - 2.16M 1.90M 1.54M 1.61M
Cash 24.63M 15.69M 15.89M 14.48M 10.48M
Cash and equivalents - - - - -
Total current liabilities 16.22M 14.86M 14.46M 13.04M 12.12M
Current deferred revenue 4.09M - 6.94M 5.31M 4.37M
Net debt -24.24300M -15.08700M -15.52000M -12.40500M -8.12900M
Short term debt 0.21M 0.30M 0.19M 0.62M 0.64M
Short long term debt - - - 0.34M 0.36M
Short long term debt total 0.39M 0.60M 0.37M 2.07M 2.35M
Other stockholder equity 0.86M 0.20M 1.65M 1.05M 2.40M
Property plant equipment - 8.47M 8.26M 8.37M 9.14M
Total current assets 48.29M 41.16M 35.10M 29.19M 25.76M
Long term investments - - - - -
Net tangible assets - - 30.75M 24.72M 22.60M
Short term investments - 3.85M 5.99M 4.38M 2.11M
Net receivables 11.21M 8.98M 7.12M 6.94M 7.76M
Long term debt - - 0.00000M 1.16M 1.40M
Inventory 11.15M 15.41M 11.31M 7.13M 6.84M
Accounts payable 5.58M 4.50M 3.82M 3.09M 2.53M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.74M 3.15M 1.65M 1.05M 2.40M
Additional paid in capital - - - - -
Common stock total equity - - - 41.59M 42.25M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M - - - 10.75M
Deferred long term asset charges - - - - -
Non current assets total 11.52M 10.64M 10.17M 9.91M 10.75M
Capital lease obligations - 0.60M 0.37M 0.57M 0.58M
Long term debt total - 0.30M 0.18M 1.46M 1.71M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.13900M -0.15500M -0.08900M -0.57900M -0.37200M
Change to liabilities 0.52M 1.26M 0.61M 0.09M -0.19100M
Total cashflows from investing activities -0.13900M -0.15500M -0.08900M -0.05400M -0.37200M
Net borrowings -0.33800M -1.53400M -0.40200M -0.57700M -0.32900M
Total cash from financing activities -3.10500M -4.38900M -3.03100M -2.19600M -3.10500M
Change to operating activities 0.08M 0.04M -0.16100M -0.00600M 0.82M
Net income 7.08M 8.29M 6.09M 3.14M 2.44M
Change in cash -0.20500M 1.42M 4.00M -0.46300M 0.98M
Begin period cash flow 15.89M 14.48M 10.48M 10.94M 9.96M
End period cash flow 15.69M 15.89M 14.48M 10.48M 10.94M
Total cash from operating activities 7.68M 5.89M 7.54M 2.03M 4.25M
Issuance of capital stock 0.58M 0.04M - - -
Depreciation 0.60M 0.41M 0.55M 0.60M 0.40M
Other cashflows from investing activities - - - - -
Dividends paid 3.04M 2.90M 1.97M 2.02M 2.02M
Change to inventory -4.10000M -4.18300M -0.28900M -0.70700M -0.95600M
Change to account receivables -1.86000M -0.17500M 0.79M -0.66200M -0.41200M
Sale purchase of stock -0.31100M 0.04M -0.65600M -0.14500M -0.75700M
Other cashflows from financing activities -0.13900M -0.15500M -0.08900M 0.52M 4.25M
Change to netincome 1.39M 0.18M -0.67700M -0.22100M 2.46M
Capital expenditures 0.14M 0.15M 0.09M 0.58M 0.37M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.13M 0.14M 0.19M 0.13M 0.11M
Stock based compensation - - - - -
Other non cash items -7.68300M -8.70100M -6.64700M -3.74000M -2.84200M
Free cash flow 7.54M 5.73M 7.46M 1.45M 3.88M

Fundamentals

  • Previous Close 2.05
  • Market Cap122.64M
  • Volume2500
  • P/E Ratio12.94
  • Dividend Yield4.07%
  • EBITDA12.10M
  • Revenue TTM74.16M
  • Revenue Per Share TTM1.38
  • Gross Profit TTM 39.74M
  • Diluted EPS TTM0.17

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VLS
Vita Life Sciences Ltd		 0.04 1.95% 2.09 12.94 - 1.73 2.97 1.41 7.98
AFP
AFT Pharmaceuticals Ltd		 0.19 7.31% 2.79 28.89 17.06 1.79 4.41 2.18 16.66
PBP
Probiotec Ltd		 0.06 2.07% 2.96 28.70 - 1.06 2.64 1.39 8.58
NXS
Next Science Ltd		 -0.01 2.56% 0.38 - 128.21 4.47 5.03 3.90 -5.9908
PER
Percheron Therapeutics Limited		 -0.001 1.32% 0.07 - - 31.54 4.38 347.00 -4.319

Reports Covered

Stock Research & News

View All

Profile

Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company also offers various minerals, herbs, and superfoods. In addition, it provides products for therapeutic areas, such as nervous system; nutritionals; urinary health; weight management; immunity; skin, hair, and nails; liver and digestion; fertility, pregnancy, and postpartum; blood sugar management; cardiovascular health; pain and inflammation; men, women, and children's health; antioxidants; bones, joints, and muscles; and eye health. The company markets its products through pharmacies and health food channels under the Herbs of Gold, VitaHealth, and VitaScience brands. Vita Life Sciences Limited was founded in 1947 and is headquartered in Kirrawee, Australia.

Vita Life Sciences Ltd

Bath Road, Kirrawee, NSW, Australia, 2232

Key Executives

Name Title Year Born
Mr. Andrew W. O'Keefe MD & Director NA
Mr. Chin Leng Khoo AGIA, C.A., C.P.A., M.B.A. CFO, Company Sec. & Acting CEO of Asia Region NA
Ms. Melissa Pereira Head of Marketing NA
Mr. Shaun Rutherford Head of Sales NA
Ms. K. S. Beh Country Head of Vita Life Sciences Malaysia & Singapore NA
Ms. June Lau Gen. Mang. of Operations & Bus. Support NA
Alexandra Ward Technical & NPD Mang. NA
Mr. Chin Leng Khoo AGIA, C.A., C.P.A., M.B.A. CFO, Company Secretary & Acting CEO of Asia Region NA
Ms. Melissa Pereira Group Marketing Manager (Leave of Absence) NA
Mr. Shaun Rutherford Chief Executive Officer of Herbs of Gold ANZ NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.